Argenx snares 2nd US nod for Vyvgart Hytrulo
Halozyme Therapeutics, Inc., a biopharmaceutical company, announced the grant of European Patent No. 4269578, covering the Enhanze rHuPH20 product obtained from Halozyme's Enhanze manufacturing methods that the company provides to its current and future licensees. The new patent is licensed under all of Halozyme's Enhanze licenses. It will be validated in 37 European countries and expires on March 6, 2029.
Argenx isn`t sweating over Vyvgart competitors: exec